MYC and neoplasm: When Myc activation was combined with the inhibition of the serine/threonine cyclin-dependent kinase 9 (CDK9), which is the kinase subunit of positive transcription elongation factor b (P-TEFb), the authors showed enhanced chemosensitivity in chemotherapy-persistent tumor cells [12].